Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2477-2489

  Malavaki, Christina J ^a   Roussidis, Andreas E ^a   Gialeli, Chrisostomi ^a,b   Kletsas, Dimitris ^c   Tsegenidis, Theodore ^a   Theocharis, Achileas D ^a   Tzanakakis, George N ^d   Karamanos, Nikos K ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

breast cancer; heparan sulfate proteoglycans; imatinib (Glivec ); invasion; migration; PDGF R

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEOHEPARAN SULFATE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CYTOSTATIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HUMANS; LIGANDS; M PHASE CELL CYCLE CHECKPOINTS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SYNDECAN-4; TRANSCRIPTOME;

EID: 84877709417     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12163     Document Type: Article

References (47)

1. Atkins JH, &, Gershell LJ, (2002) Selective anticancer drugs. Nat Rev Drug Discov 1, 491-492.
2. Dickson RB, &, Lippman ME, (1995) Growth factors in breast cancer. Endocr Rev 16, 559-589.
3. Hines SJ, Litz JS, &, Krystal GW, (1999) Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors. Breast Cancer Res Treat 58, 1-10. (Pubitemid 30003865)
4. Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, &, Silvestrini R, (2004) c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat 83, 33-42. (Pubitemid 38141891)
5. Heldin CH, Eriksson U, &, Ostman A, (2002) New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398, 284-290. (Pubitemid 34848597)
6. Sun PD, &, Davies DR, (1995) The cystine-knot growth-factor superfamily. Annu Rev Biophys Biomol Struct 24, 269-291.
7. Reigstad LJ, Varhaug JE, &, Lillehaug JR, (2005) Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 272, 5723-5741. (Pubitemid 41689346)
8. Tallquist M, &, Kazlauskas A, (2004) PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15, 205-213. (Pubitemid 38781046)
9. Zafiropoulos A, Fthenou E, Chatzinikolaou G, &, Tzanakakis GN, (2008) Glycosaminoglycans and PDGF signaling in mesenchymal cells. Connect Tissue Res 49, 153-156.
10. Betsholtz C, Karlsson L, &, Lindahl P, (2001) Developmental roles of platelet-derived growth factors. BioEssays 23, 494-507. (Pubitemid 32575610)
11. Bonner JC, (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15, 255-273. (Pubitemid 38781050)
12. Raines EW, (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15, 237-254. (Pubitemid 38781049)
13. Ostman A, (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15, 275-286. (Pubitemid 38781051)
14. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, &, Ostman A, (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175, 334-341.
15. Sariban E, &, Kufe D, (1988) Expression of the platelet-derived growth factor 1 and 2 genes in human myeloid cell lines and monocytes. Cancer Res 48, 4498-4502.
16. Brown RE, Lun M, Prichard JW, Blasick TM, &, Zhang PL, (2004) Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 34, 251-262. (Pubitemid 39166987)
17. Theocharis AD, Gialeli C, Hascall V, &, Karamanos N, (2012) Extracellular Matrix: A Functional Scaffold. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed), pp 3-20. De Gruyter, Berlin.
18. Theocharis AD, Skandalis SS, Tzanakakis GN, &, Karamanos NK, (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
19. Iozzo RV, &, Sanderson RD, (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 1013-1031.
20. Sanderson RD, (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12, 89-98.
21. Gialeli C, Theocharis AD, &, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
22. Almendral JM, Sommer D, Macdonald-Bravo H, Burckhardt J, Perera J, &, Bravo R, (1988) Complexity of the early genetic response to growth factors in mouse fibroblasts. Mol Cell Biol 8, 2140-2148.
23. Nikitovic DPH, Berdiaki A, Gialeli C, Kletsas D, &, Tzanakakis GN, (2012) Growth Factor Signaling and Extracellular. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed), pp 741-762. De Gruyter, Berlin.
24. Roussidis AE, &, Karamanos NK, (2002) Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. In Vivo 16, 459-469. (Pubitemid 35460363)
25. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al,. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031-1037. (Pubitemid 32267972)
26. Joensuu H, &, Dimitrijevic S, (2001) Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33, 451-455. (Pubitemid 32959916)
27. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, et al,. (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62, 4879-4883. (Pubitemid 34984407)
28. Krystal GW, Honsawek S, Litz J, &, Buchdunger E, (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6, 3319-3326. (Pubitemid 30637763)
29. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, &, Salgia R, (2000) Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19, 3521-3528. (Pubitemid 30487449)
30. Moelling K, Schad K, Bosse M, Zimmermann S, &, Schweneker M, (2002) Regulation of Raf- Akt Cross-talk. J Biol Chem 277, 31099-31106.
31. Fukazawa H, Noguchi K, Murakami Y, &, Uehara Y, (2002) Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 1, 303-309.
32. Roussidis AE, Theocharis AD, Tzanakakis GN, &, Karamanos NK, (2007) The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr Med Chem 14, 735-743. (Pubitemid 46477708)
33. Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, &, Mundhenke C, (2009) Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett 273, 70-79.
34. Dedes PG, Gialeli C, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D, Tzanakakis GN, &, Karamanos NK, (2012) Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 1820, 1926-1939.
35. Roussidis AE, Mitropoulou TN, Theocharis AD, Kiamouris C, Papadopoulos S, Kletsas D, &, Karamanos NK, (2004) STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells. Anticancer Res 24, 1445-1447. (Pubitemid 38954662)
36. Pietras K, Sjoblom T, Rubin K, Heldin CH, &, Ostman A, (2003) PDGF receptors as cancer drug targets. Cancer Cell 3, 439-443. (Pubitemid 38340290)
37. Ostman A, &, Heldin CH, (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97, 247-274. (Pubitemid 46528991)
38. Wu E, Palmer N, Tian Z, Moseman AP, Galdzicki M, Wang X, Berger B, Zhang H, &, Kohane IS, (2008) Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 3, e3794.
39. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N, &, San Miguel JF, (2003) Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 123, 858-868. (Pubitemid 37533298)
40. Abouantoun TJ, &, MacDonald TJ, (2009) Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol Cancer Ther 8, 1137-1147.
41. Manon-Jensen T, Itoh Y, &, Couchman JR, (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 3876-3889.
42. Lendorf ME, Manon-Jensen T, Kronqvist P, Multhaupt HA, &, Couchman JR, (2011) Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem 59, 615-629.
43. Xian X, Gopal S, &, Couchman JR, (2010) Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res 339, 31-46.
44. Yoneda A, Lendorf ME, Couchman JR, &, Multhaupt HA, (2012) Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem 60, 9-21.
45. Kousidou O, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, &, Karamanos NK, (2008) Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2, 223-232.
46. Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP, &, Karamanos NK, (2003) Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 104, 155-160. (Pubitemid 36249789)
47. Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, Kletsas D, &, Karamanos NK, (2007) Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer 121, 2808-2814. (Pubitemid 350136431)